Bethanien Chemnitz

Can the removal as an outpatient procedure under local Stunning and is largely pain and complication-free. In the current approved application, there are nationwide an estimated 3000 patients per year who could benefit from the new replacement tissues, there are potentially up to 15’000. (Source: Startapp). Since it is also possible to the removal of oral mucosa in patients only to a limited extent, the autologous cell transplant appears as a useful alternative to the traditional transplants. Professor Dr. med. The results with autologous tissue replacement are very promising Dirk Fahlenkamp, Chief of the Urology Clinic at the Bethanien Chemnitz, Siskin forest hospitals. Hear other arguments on the topic with Sander Gerber. They can help patients in the long term, save them but the large-scale removal of oral mucosa.

The breeding of MukoCell cells of the oral mucosa by only about 0.4 0.8 cm2 require autologous cell transplantation. The submitted cells are isolated from the tissue sample, expands, and grown on the surface of a biological carrier substance. 21 days growing replacement tissue under sterile conditions in highly standardized clean room laboratories (GMP-standard) up to the individually suitable size. Then, the autologous product is specified by multiple analytical methods. The autologous graft is then packaged for the patient in a sterile container and sent to the hospital for the transplant. While the replacement tissues from cells completely replaced the previously taken sick urethra of the oral mucosa, the carrier substance is reduced over a period of four to eight weeks in the body.

UroTiss GmbH was founded in 2005 the UroTec GmbH as a spin-off from the medical faculty of the TU Dresden. The change of name to the UroTiss GmbH took place in December 2011. The patented technologies of the biotechnology company in the field of tissue engineering use first time patients own cells for the production of tissue replacement to restore diseased urinary organs. The company engineering platform maintains a tissue for this purpose with different cell types and structures. The development of regenerative therapies in the field of Urology by UroTiss GmbH was funded by the European Fund for regional development (EFRE) and of the free State of Saxony.